Adherium has announced that AstraZeneca will use Adherium’s SmartTouch Symbicort device in an upcoming 12-month clinical study of adherence in patients with COPD that is expected to enroll almost 400 US COPD patients. In July 2015, Adherium announced a deal to supply SmartInhaler technology for AstraZeneca’s asthma and COPD patient support programs.
According to Adherium, its SmartInhaler platform, which has received FDA 510(k) clearance, has been used in 63 projects to date, including clinical trials and device validation studies.
Adherium CEO Garth Sutherland commented, “This study is important research because adherence rates in COPD patients are low, and Adherium’s Smartinhaler is the gold standard in recording and improving medication adherence in chronic lung disease. Adherium is supplying the technology platform for this study under the long term Master Supply and Development Agreement already entered into with AstraZeneca.”
Read the Adherium press release.
